A Critical Evaluation of the Role of Lp(a) in Cardiovascular Disease: Can Lp(a) Be Useful in Risk Assessment?

Seminars in Vascular Medicine

Volumn 2, Issue 3, 2002, Pages 335-344

  Marcovina, Santica M ^a   Koschinsky, Marlys L ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

apolipoprotein(a); atherosclerosis; coronary heart disease; Lipoprotein(a)

Indexed keywords

LIPOPROTEIN A;

CARDIOVASCULAR DISEASE; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEIN(A);

EID: 0038808693     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-35404     Document Type: Article

References (85)

1. Berg K. A new serum type system in man: the Lp system. Acta Pathol Microbiol Scand 1963;59:362–382
2. Cheng SW, Ting AC, Wong J. Lipoprotein(a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. Eur Vase Endovasc Surg 1997;14:17–23
3. Peng DQ, Zhao SP, Wang JL. Lipoprotein(a) and apolipoprotein E epsilon 4 as independent risk factors for ischemic stroke. J Cardiovasc Risk 1999;6:1–6
4. Marcovina SM, Hegele RA, Koschinsky ML. Lipoprotein(a) and coronary heart disease risk. Curr Cardiol Rep 1999;1: 105–111
5. Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 1998;82:57U-66U
6. Craig WY, Neveux LM, Palomaki GE, et al. Lipoprotein(a) as a risk factor for ischemic heart disease: meta-analysis of prospective studies. Clin Chem 1998;44:2301–2306
7. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies. Circulation 2000;102:1082–1085
8. Armstrong VW, Cremer P, Eberle E, et al. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis 1986;62:249–257
9. Maher VM, Brown BG, Marcovina SM, et al. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995;274:1771–1774
10. Hopkins PN, Wu LL, Hunt SC, et al. Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vase Biol 1997; 17:2783–2792
11. Cantin B, Gagnon F, Moorjani S, et al. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 1998; 31:519–525
12. Kronenberg F, Kronenberg MF, Kiechl S, et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck Study. Circulation 1999;100:1154–1160
13. van Eckardstein A, Schulte H, Cullen P, et al. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001;37:434–439
14. Marcovina SM, Koschinsky ML. Lipoprotein(a): Structure, measurement, and clinical significance. In: Rifai, N, Warnick, GR, Dominiczak MH, eds. Handbook of Lipoprotein Testing, Ed. 2. Washington, DC: AACC Press: 345–385
15. Angelin B. Therapy for lowering lipoprotein(a) levels. Curr Opin Lipidol 1997;8:337–341
16. Albers JJ, Kennedy H, Marcovina SM. Evidence that Lp(a) contains one molecule of apo(a) and one molecule of apo B: evaluation of amino acid analysis data. J Lipid Res 1996;37: 192–196
17. Koschinsky ML, Côté GP, Gabel BR, et al. Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100. J Biol Chem 1993;268:19819–19825
18. Callow MJ, Rubin EM. Site-specific mutagenesis demonstrates that cysteine 4326 of apolipoprotein B is required for covalent linkage with apolipoprotein(a) in vivo. J Biol Chem 1995;270:23914–23917
19. Trieu VN, McConathy WF. A two-step model for lipoprotein(a) formation. J Biol Chem 1995;270:15471–15474
20. Gabel BR, Koschinsky ML. Sequences within apolipoprotein(a) kringle IV types 6–8 bind directly to low-density lipoprotein and mediate noncovalent association of apolipoprotein(a) with apolipoprotein B-100. Biochemistry 1998;37: 7892–7898
21. Becker L, McLeod, R, Marcovina SM, et al. Identification of a critical lysine residue in apolipoprotein B-100 that mediates noncovalent interaction with apolipoprotein(a). J Biol Chem, in press
22. Xu S. Apolipoprotein(a) binds to low density lipoprotein at two distant sites in lipoprotein(a). Biochemistry 1998;37: 9284–9294
23. White AL, Rainwater DL, Lanford RE. Intracellular maturation of apolipoprotein(a) and assembly of lipoprotein(a) in primary baboon hepatocytes. J Lipid Res 1993;34:509–517
24. Frank S, Krasznai K, Durovic S, et al. High-level expression of various apolipoprotein(a) isoforms by “transferrinfection”: the role of kringle IV sequences in the extracellular association with low-density lipoprotein. Biochemistry 1994;33: 12329–12339
25. White, AL, Lanford, RE. Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes. J Biol Chem 1994;269:28716–28723
26. Fless GM, ZumMallen ME, Scanu AM. Physicochemical properties of apolipoprotein(a) and lipoprotein(a-) derived from the dissociation of human plasma lipoprotein(a). J Biol Chem 1986;261:8712–8718
27. Kraft HG, Menzel HJ, Hopplichler F, et al. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J Clin Invest 1989;83:137–140
28. McLean JW, Tomlinson JE, Kuang W-J, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;330:132–137
29. Lackner C, Cohen JC, Hobbs HH. Molecular definition of the extreme size polymorphism in apolipoprotein(a). HumMol Genet 1993;2:933–940
30. van der Hoek YY, Wittekoek ME, Beisiegel U, et al. The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms. Hum Mol Genet 1993;2:361–366
31. Sangrar W, Marcovina SM, Koschinsky, ML. Expression and characterization of apolipoprotein(a) kringle IV types 1, 2 and 10 in mammalian cells. Protein Eng 1993;7:723–731
32. Gabel BR, May LF, Marcovina SM, et al. Lipoprotein(a) Assembly. Quantitative assessment of the role of apo(a) kringle IV types 2–10 in particle formation. Arterioscler Thromb Vase Biol 1996;16:1559–1567
33. Ernst A, Helmhold M, Brunner C, et al. Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32–36 of human apolipoprotein(a). J Biol Chem 1994;270:6227–6234
34. Utermann G, Menzel HJ, Kraft HG, et al. Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987;80:458–465
35. Brunner C, Lobentanz EM, Petho-Schramm A, et al. The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells. J Biol Chem 1996;13:32403–32410
36. Gaw A, Brown EA, Ford I. Impact of apo(a) length polymorphism and the control of plasma Lp(a) concentrations: evidence for a threshold effect. Arterioscler Thromb Vase Biol 1998;18:1870–1876
37. Rath M, Niendorf A, Reblin T, et al. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989;9:579–592
38. Fan J, Shimoyamada H, Sun H, et al. Transgenic rabbits expressing human apolipoprotein(a) develop more extensive atherosclerotic lesions in response to a cholesterol-rich diet. Arterioscler. Thromb. Vase. Biol 2001;21:88–94
39. Dangas G, Mehran R, Harpel PC, et al. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol 1998; 32:2035–2042
40. Hoff HF, O'Neil J, Yashiro A. Partial characterization of lipoproteins containing apo(a) in human atherosclerotic lesions. J Lipid Res 1993;34:789–798
41. Scanu AM. Proteolytic modifications of lipoprotein(a): potential relevance to its postulated atherothrombogenic role. J Investig Med 1998;46:359–363
42. Edelstein C, Italia JA, Scanu AM. Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase. J Biol Chem 1997;272:11079–11087
43. Edelstein C, Shapiro SD, Klezovitch O, et al. Matrix metalloelastase, MMP-12, cleaves human apolipoprotein(a) in the linker region between kringles IV-4 and IV-5. J Biol Chem 1999;274:10019–10023
44. Scanu AM, Edelstein C, Klezovitch O. Dominant role of the C-terminal domain in the binding of apolipoprotein(a) to the protein core of proteoglycans and other members of the vascular matrix. Trends Cardiovasc Med 1999;9:196–200
45. Mooser V, Marcovina SM, White AL, et al. Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J Clin Invest 1996;98:2414–2424
46. Mooser V, Seabra MC, Abedin M, et al. Apolipoprotein(a) kringle 4-containing fragments in human urine. J Clin Invest 1996;97:858–864
47. Kostner KM, Maurer G, Huber K, et al. Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. Arterioscler Thromb Vase Biol 1996;16:905–911
48. Haberland ME, Fless GM, Scanu AM, et al. Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. J Biol Chem 1992;267: 4143–4151
49. Naruszewicz M, Selinger E, Davignon J. Oxidative modification of lipoprotein(a) and the effect of beta-carotene. Metabolism 1992;41:1215–1224
50. Sattler W, Kostner GM, Waeg G, et al. Oxidation of lipoprotein Lp(a). A comparison with low density lipoproteins. Biochim Biophys Acta 1991;1081:65–74
51. Jurgens G, Chen Q, Esterbauer H, et al. Immunostaining of human autopsy aortas with antibodies to modified apolipoprotein B and apolipoprotein(a). Arterioscler Thromb 1993; 13:1689–1699
52. Scanu AM. Atherothrombogenicity of lipoprotein(a): the debate. Am J Cardiol 1998;82:26Q-33Q.
53. Hoover-Plow J, Khaitan A, Fless GM. Phospholipase A2 modification enhances lipoprotein(a) binding to the subendothelial matrix. Thromb Haemost 1998;79:640–648
54. Carmeliet P, Collen D. Gene manipulation and transfer of the plasminogen and coagulation system in mice. Semin Thromb Hemost 1996;22:525–542
55. Sangrar W, Bajzar L, Nesheim ME, et al. The antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation. Biochemistry 1995;34:5151–5157
56. Palabrica TM, Liu AC, Aronovitz MJ, et al. Antifibrinolytic effect of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med 1995;1:256–259
57. Biemond BJ, Friederich PW, Koschinsky ML, et al. Apolipoprotein(a) attenuates fibrinolysis in the rabbit jugular vein thrombosis model in vivo. Circulation 1997;96:1612–1615
58. Rand ML, Sangrar W, Hancock MA, et al. Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide, SFLLRN. Arterioscler Thromb Vase Biol 1998;18:1393–1399
59. Etingen OR, Hajjar DP, Hajjar KA, et al. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem 1991;266:2459–2465
60. Li XN, Grenett HE, Benza RL, et al. Genotype-specific transcriptional regulation of PAI-1 expression by hypertriglyceri-demic VLDL and Lp(a) in cultured human endothelial cells. Arterioscler Thromb Vase Biol 1997;17:3215–3223
61. Buechler C, Ullrich H, Ritter M, et al. Lipoprotein(a) up-reg-ulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes. Blood 2001;97:981–986
62. Kojima S, Harpel PC, Rifkin DB. Lipoprotein(a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol 1991;113:1439–1445
63. Grainger DJ, Kirschenlohr HL, Metcalfe JC, et al. The proliferation of human smooth muscle cells is promoted by lipoprotein(a). Science 1993;260:1655–1658
64. Grainger DJ, Kemp PR, Liu AC, et al. Activation of transforming growth factor beta is inhibited in transgenic apolipoprotein(a) mice. Nature 1994;370:460–462
65. Desmaris RL, Sarembock IJ, Ayers CR, et al. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 1995;91:1403–1409
66. Miyata M, Biro S, Arima S, et al. High serum concentration of lipoprotein(a) is a risk factor for restenosis after percutaneous transluminal coronary angioplasty in Japanese patients with single-vessel disease. Am Heart J 1996;130:269–273
67. Adams MR, Kinlay S, Blake CJ, et al. Atherogenic lipids and endothelial dysfunction: mechanisms in the genesis of ischemic disorders. Annu Rev Med 2000;51:149–167
68. Haque N, Zhang X, French DL, et al. CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells. Circulation 2000;102:786–792
69. Allen S, Khan S, Tarn S-P, et al. Expression of adhesion molecules by Lp(a): a potential novel mechanism for its atherogenicity. FASEB J 1998;12:1765–1776
70. Zhao SP, Xu DY. Oxidized lipoprotein(a) enhanced the expression of P-selectin in cultured human umbilical vein endothelial cells. Thromb Res 2000;100:501–510
71. Takami S, Yamashita S, Kihara S, et al. Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. Circulation 1998;97:721–728
72. Zhao SP, Xu DY. Oxidized lipoprotein(a) increases the expression of platelet-derived growth factor-B in human umbilical vein endothelial cells. Clin Chim Acta 2000;296:121–133
73. Galle J, Schneider R, Heinloth A, et al. Lp(a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: role of oxidative stress. Kidney Int 1999;55:1450–1461
74. Schachinger V, Halle M, Minners J. Lipoprotein(a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation. J Am Coll Cardiol 1997;30:927–934
75. Moeslinger T, Friedl T, Volf I, et al. Inhibition of inducible nitric oxide synthesis by oxidized lipoprotein(a) in a murine macrophage cell line. FEBS Lett 2000;478:95–99
76. Zampoulakis JD, Kyriakousi AA, Poralis KA, et al. Lipoprotein(a) is related to the extent of lesions in the coronary vasculature and to unstable coronary syndromes. Clin Cardiol. 2000;23:895–900
77. Ganne F, Vasse M, Beaudeux JL, et al. Increased expression of u-PA and u-PAR on monocytes by LDL and Lp(a) lipoproteins-consequences for plasmin generation and monocyte adhesion. Thromb Haemost 1999;81:594–600
78. Fortunato JE, Bassiouny HS, Song RH, et al. Apolipoprotein(a) fragments in relation to human carotid plaque instability. J Vase Surg 2000;32:555–563
79. Kraft HG, Lingenhel A, Kochl S, et al. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary artery disease. Arterioscler Thromb Vase Biol 1996;16:713–719
80. Linden T, Taddei-Peters W, Wilhelmsen L, et al. Serum lipids, lipoprotein(a) and apo(a) isoforms in patients with established coronary artery disease and their relation to disease and prognosis after coronary by-pass surgery. Atherosclerosis 1998;137:175–186
81. Marcovina SM, Albers JJ, Wijsman E, et al. Differences in Lp(a) concentrations and apo(a) polymorphs between Black and White Americans. J Lipid Res 1996;37:2569–2585
82. Paultre F, Pearson TA, Weil HF, et al High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vase Biol 2000;20:2619–2624
83. Wild SH, Fortmann SP, Marcovina SM. A prospective case control study of lipoprotein levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vase Biol 1997;17:239–245
84. Hervio L, Girard-Globa A, Durlach A, et al. The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentrations of each of the apolipoprotein(a) isoforms and their affinity for fibrin. Eur J Clin Invest 1996;26:411–417
85. Koschinsky ML, Marcovina SM. The effect of hormone replacement therapy on lipoprotein(a) levels in post-meno-pausal women. Cardiovascular Rev Rep 1999;7:387–394